US pharma major Bristol Myers Squibb (NYSE: BMY) closed higher on Friday following news on a new product named Opdualag (nivolumab and relatlimab-rmbw).
The fixed dose combination was approved by the US Food and Drug Administration (FDA) for the treatment of adult and pediatric patients aged 12 years of age or older with unresectable or metastatic melanoma.
"Inhibiting LAG-3 with relatlimab, in a fixed-dose combination with nivolumab, represents a new treatment approach that builds on our legacy of bringing innovative immunotherapy options to patients"This approval is based on the Phase II/III RELATIVITY-047 trial, which compared Opdualag to nivolumab alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze